Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease
Yuanqiang Ma, Gyurim Lee, Suyoung Heo, et al.
Antioxidants (2021) Vol. 11, Iss. 1, pp. 91-91
Open Access | Times Cited: 134

Showing 1-25 of 134 citing articles:

Oxidative Stress in Liver Pathophysiology and Disease
Abdolamir Allameh, Reyhaneh Niayesh‐Mehr, Azadeh Aliarab, et al.
Antioxidants (2023) Vol. 12, Iss. 9, pp. 1653-1653
Open Access | Times Cited: 150
Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model
Raimundo Gillet, Tomás G. Cerda-Drago, María C. Brañes, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 564-564
Open Access | Times Cited: 2
Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease
Alfredo Smiriglia, Nicla Lorito, Marina Bacci, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Reactive Oxygen Species: Role in Pathophysiology, and Mechanism of Endogenous and Dietary Antioxidants during Oxidative Stress
Mohammad Mamun Sikder, Xiaodong Li, Steeve Akumwami, et al.
Chonnam Medical Journal (2025) Vol. 61, Iss. 1, pp. 32-32
Open Access | Times Cited: 2
Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease
Vidyasagar Naik Bukke, Archana Moola, Gaetano Serviddio, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 48, pp. 6909-6921
Open Access | Times Cited: 46
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Keisuke Sawada, Hak‐Jae Chung, Samir Softic, et al.
Cell Metabolism (2023) Vol. 35, Iss. 11, pp. 1852-1871
Open Access | Times Cited: 37
Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress
Pin Gong, Hui Long, Yuxi Guo, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 116927-116927
Closed Access | Times Cited: 32
Radical oxygen species: an important breakthrough point for botanical drugs to regulate oxidative stress and treat the disorder of glycolipid metabolism
Maocai Luo, Yuhong Zheng, Shiyun Tang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 31
Bioactive Compounds in Moringa oleifera: Mechanisms of Action, Focus on Their Anti-Inflammatory Properties
Adina Chiş, Paul Aimé Noubissi, Oana Lelia Pop, et al.
Plants (2023) Vol. 13, Iss. 1, pp. 20-20
Open Access | Times Cited: 31
Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
Gao-Xin Xu, Wei Song, Chao Yu, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 29
Oxidative Stress and MicroRNAs in Endothelial Cells under Metabolic Disorders
Morgan Minjares, Wendy Wu, Jie‐Mei Wang
Cells (2023) Vol. 12, Iss. 9, pp. 1341-1341
Open Access | Times Cited: 26
Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor
S Kamata, Akihiro Honda, Ryo Ishikawa, et al.
Antioxidants (2023) Vol. 12, Iss. 8, pp. 1523-1523
Open Access | Times Cited: 24
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression
Yue-fan Wang, Wenli Zhang, Zhi-xuan Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 14
Berberine prevents NAFLD and HCC by modulating metabolic disorders
Xinyue Lin, Jilei Zhang, Yajun Chu, et al.
Pharmacology & Therapeutics (2024) Vol. 254, pp. 108593-108593
Closed Access | Times Cited: 13
Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease
Caiyun Wu, Siyuan Xiang, Haitao Wang, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 8, pp. 9854-9867
Closed Access | Times Cited: 13
Oligonucleotide therapies for nonalcoholic steatohepatitis
Sixu Li, Feng Xiong, Songbo Zhang, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 2, pp. 102184-102184
Open Access | Times Cited: 9
Recent progress in small molecule fluorescent probes for imaging and diagnosis of non-alcoholic fatty liver disease
Yongqing Zhou, Xiaofeng Yang, Xianzhe Wei, et al.
Coordination Chemistry Reviews (2024) Vol. 513, pp. 215864-215864
Closed Access | Times Cited: 9
A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease
Sara Mighani, Rasoul Samimi, Mohammadreza Rashidi Nooshabadi, et al.
BMC Complementary Medicine and Therapies (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Ramulus Mori (Sangzhi) Alkaloids Alleviate High-Fat Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice
Yanmin Chen, Chunfang Lian, Qian-Wen Sun, et al.
Antioxidants (2022) Vol. 11, Iss. 5, pp. 905-905
Open Access | Times Cited: 34
NOX as a Therapeutic Target in Liver Disease
Deyamira Matuz‐Mares, Héctor Vázquez‐Meza, María Magdalena Vilchis‐Landeros
Antioxidants (2022) Vol. 11, Iss. 10, pp. 2038-2038
Open Access | Times Cited: 30
NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook
Alberto Nascè, Karim Gariani, François R. Jornayvaz, et al.
Antioxidants (2022) Vol. 11, Iss. 6, pp. 1131-1131
Open Access | Times Cited: 29
A Comprehensive Review of the Pharmacological Importance of Dietary Flavonoids as Hepatoprotective Agents
Gajender, Avijit Mazumder, Ashwani Sharma, et al.
Evidence-based Complementary and Alternative Medicine (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 21
Thioredoxin/Glutaredoxin Systems and Gut Microbiota in NAFLD: Interplay, Mechanism, and Therapeutical Potential
Minghui Zhu, Omer M. A. Dagah, Billton Bryson Silaa, et al.
Antioxidants (2023) Vol. 12, Iss. 9, pp. 1680-1680
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top